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Abstract 
Policy responses to COVID-19, particularly those related to non-pharmaceutical interventions, 
are unprecedented in scale and scope. Researchers and policymakers are striving to 
understand the impact of these policies on a variety of outcomes. Policy impact evaluations 
always require a complex combination of circumstance, study design, data, statistics, and 
analysis. Beyond the issues that are faced for any policy, evaluation of COVID-19 policies is 
complicated by additional challenges related to infectious disease dynamics and lags, lack of 
direct observation of key outcomes, and a multiplicity of interventions occurring on an 
accelerated time scale. 
 
In this paper, we (1) introduce the basic suite of policy impact evaluation designs for 
observational data, including cross-sectional analyses, pre/post, interrupted time-series, and 
difference-in-differences analysis, (2) demonstrate key ways in which the requirements and 
assumptions underlying these designs are often violated in the context of COVID-19, and (3) 
provide decision-makers and reviewers a conceptual and graphical guide to identifying these 
key violations. The overall goal of this paper is to help policy-makers, journal editors, journalists, 
researchers, and other research consumers understand and weigh the strengths and limitations 
of evidence that is essential to decision-making. 
Introduction 
The response to the global COVID-19 pandemic has demanded urgent decision making in the 
face of substantial uncertainties. Policies to arrest transmission, including stay-at-home orders 
and other non-pharmaceutical interventions (NPIs), have wide-reaching consequences that 
touch many aspects of well being. Decision-making in the public interest requires evaluating and 
weighing the evidence on both intended and unintended consequences in order to best predict 
outcomes (1–3). The wide range of policy interventions implemented by different jurisdictions 
may yield opportunities for learning from what has already happened to inform future 
policymaking, and we have observed a proliferation of studies aimed at such policy evaluations 
(4). However, policy evaluation requires a complex combination of circumstance, data, study 
design, analysis, and interpretation in order to be informative. 
 
Policy impact evaluation aims to answer questions about the extent to which the realized 
outcomes given a particular policy would have been different in the absence of that policy. 
Estimating the causal impact of the policy with observational data is challenging because what 
would have happened in the absence of the policy change (the “counterfactual”) is, by definition, 
unobserved. Randomized controlled trials (RCTs) of policies related to COVID-19 interventions 
may not always be practical or ethical (5). In this context, a large and growing number of studies 
have attempted to evaluate the impact of COVID-19 policies using observational data. There 
are many potential pitfalls in the use of observational data for evaluation generally, and some 
additional methodological design challenges relating to COVID-19 policies in particular.  
 
This paper provides a graphical guide to policy impact evaluations for COVID-19, targeted to 
decision-makers, researchers and evidence curators. Our aim is to provide a coherent 
framework for conceptualizing and identifying common pitfalls in COVID-19 policy evaluation. 
Importantly, this should not be taken either as a comprehensive guide to policy evaluation more 
broadly or as guidance on performing analysis, which may be found elsewhere (6–10). Rather, 
we review relevant study designs for policy evaluations — including pre/post, interrupted time 
series, and difference-in-difference approaches — and provide guidance and tools for 
identifying key issues with each type of study as they relate to NPIs and other COVID-19 policy 
interventions. Improving our ability to identify key pitfalls will enhance our ability to identify and 
produce valid and useful evidence for informing policymaking. 
Common policy evaluation designs and their pitfalls 
in COVID-19 
Identifying the type of design 
  
Table 1: Summary definitions of policy impact evaluation designs commonly used for COVID-19  
 
Design Units (e.g., regions of 
comparison) 
Time points measured per unit  
Assumed counterfactual. 
 
“If not for the intervention, 
___” 
With 
intervention 
Without 
intervention 
Before 
intervention 
After intervention 
Cross-sectional At least one At least one N/A One time point Outcome in intervention units 
would have been the same as 
the outcome in the 
non-intervention units. 
Pre/post 
Figure 1A 
At least one None At least one 
(typically one) 
At least one (typically 
one) 
Outcome would have stayed 
the same from the pre period 
to the post period. 
Interrupted 
time-series 
(ITS) 
Figure 1B 
At least one None More than one At least one (typically 
several) 
Outcome slope and level* 
would have continued along 
the same modelled trajectory 
from the pre-period to the post 
period. 
Difference-in-diff
erences 
(DiD) 
Figure 1C 
At least one At least one At least one 
(typically one) 
At least one (typically 
one) 
Outcome in intervention units 
would have changed as much 
as (or in parallel with) the 
outcome in the 
non-intervention units. 
Comparative 
interrupted time 
series (CITS) 
Figure 1D 
At least one At least one More than one 
(typically 
several) 
At least one (typically 
several) 
Outcome slope and level* 
would have changed as much 
as non-intervention group’s 
slope and level* changed. 
* Assessing both slope and level only applicable if there are multiple data points during the post period 
 
Identifying the underlying design in a given analysis often requires using a combination of the 
methods as reported and evaluating the data structure that is used for the main analysis, as 
shown in Table 1. COVID-19-related policy evaluation analyses typically fall under these 
categories. In most cases, the design can be categorized using a combination of whether there 
are also units that did not receive the treatment (columns 2-3) and whether there are time points 
both before and after intervention for those units (columns 4-5). The final column describes the 
implied counterfactual, discussed further in subsequent sections.  
 
Methods descriptions may not always provide a precise or reliable guide to which of the design 
approaches has been used. Some studies do not explicitly name these designs (or may classify 
them differently); and these are only a small fraction of designs and frameworks that are 
possible to use for policy evaluation (6,11,12). Studies may have data at multiple time points but 
are effectively cross-sectional (13). DiD, ITS, and CITS designs based on repeated 
cross-sectional data are sometimes described as “cross-sectional,” (14,15) instead of 
longitudinal. The term “event study” is often used to refer to studies with a single unit and one 
change over time resembling ITS (16,17), but may refer to other designs. Although ITS is often 
used to describe changes in one unit, it may also refer to settings in which many treated units 
adopt an intervention over time (18–23). Studies will also frequently employ multiple designs 
(24), while others use more complex methods of generating counterfactuals (16). Definitions of 
these designs vary widely, and the definitions above should be considered as guidance only. 
Policy impact evaluation design foundations for COVID-19 
The simplest design is the cross-sectional analysis, which compares COVID-19 outcomes 
between units of observation (e.g., cities) at a single calendar time or time since an event, 
typically post-intervention. These studies are unlikely to be appropriate for COVID-19-related 
policy evaluations, but provide a useful starting point for reasoning about different designs. Just 
as with comparisons of non-randomized medical treatments, the localities that adopt a particular 
policy likely differ substantially from those that don't on both observed and unobserved 
characteristics on a number of dimensions, including epidemic status and timing. 
 
Figure 1: Longitudinal designs overview 
  
This chart shows four canonical longitudinal designs. In all cases: the blue shading 
represents the underlying data trends, the solid vertical grey line represents the time of 
intervention, the grey dashed lines represent the assumed counterfactual in the absence of 
the intervention, as discussed in the text. The impact estimate is obtained by comparing the 
outcomes observed for the treated unit in the post period (the solid line) with the implied 
counterfactual line (the dashed line). In the case of the pre/post and 
difference-in-differences panels the large black dots represent the time of measurement, 
connected by the grey dotted lines. 
 
Given the challenges in a simple cross-sectional comparison, which compare post-intervention 
outcomes, it is important to consider longitudinal designs, which instead look at differences or 
trends across time, as summarized in Figure 1. These can be distinguished by the data used 
and the construction of the counterfactual. Pre/post, for example, has only one unit, measured 
at two time points. Two common strategies expand on the logic and data requirements of the 
pre/post design. Interrupted time series designs (Figure 1B) incorporate multiple time points 
before the intervention, and usually multiple time points after the intervention, to enable a more 
complete view on changes in levels and trends that are temporally related to the intervention. 
Difference-in-difference designs (Figure 1C) add a set of comparison points from a group or 
location that did not have the intervention. Another related design (comparative interrupted 
time-series, Figure 1D, discussed only briefly here), uses both aspects — a change over time 
and a comparison group — to compare the observed change in slopes for the intervention 
group with the change in slope for the comparison group. 
Pre/post studies  
The simplest longitudinal design is a pre/post analysis, where some outcome is observed before 
policy implementation, and again after, in a single group (Figure 1A). Pre/post studies are 
analogous to a single arm trial (26) with no control and only a single follow-up observation after 
treatment.. This effectively imposes the assumption that the counterfactual trend is completely 
flat (i.e., that the outcome in the post-period in the absence of the policy change is the same as 
the value of the outcome before the policy change) without accounting for pre-existing 
underlying trends, and attributing all outcome changes completely to the intervention of interest. 
Just as the outcomes for an individual patient might be expected to change before and after 
treatment, for reasons unrelated to the treatment, outcomes related to policy interventions will 
change for reasons not caused by the policy. Infection rates, for example, would not be 
expected to remain stationary except in very specific circumstances, but a pre/post 
measurement would assume that any changes in infection rates are attributable to the policy. 
Interrupted time-series 
Figure 2: Interrupted time-series 
 
This chart shows one canonical design for ITS (blue, Panel A) and four panels demonstrating 
common issues with ITS analysis (red, panels B-E) discussed in the text. In all cases: the 
lag/red shading represents the underlying data trends, the vertical grey line represents the 
time of intervention, the grey dashed lines represent the assumed counterfactual in the 
absence of the intervention. In panel D) the dash-dot line represents the time at which the 
policy is expected to impact the outcome. In panel E), the vertical dotted lines represent 
concurrent events and changes. 
 
Interrupted time-series (ITS) is a strategy that uses a projection of the pre-policy outcome trend 
as a counterfactual for how the outcome would have changed if the policy had not been 
introduced. In other words, in the absence of the policy change, ITS assumes the outcome 
would have continued on its pre-policy trend during the study period. ITS can be a useful tool in 
policy evaluation because it allows researchers to account for underlying trends in the outcome 
and, by comparing the treated unit (or location) to itself; it can therefore eliminate some of the 
confounding concerns that arise in cross-sectional or pre-post studies. 
 
However, the validity of ITS depends critically on how well counterfactual trends in the outcome 
are modelled, and whether the policy of interest is the only relevant change during the study 
period. In the canonical setting (Figure 2A), the pre-policy trend is stable and can be feasibly 
modelled with the available data; the researcher appropriately models the timing of the change 
in the slope and/or level of the outcome; the researcher has sufficient information to conclude 
that there were no other changes during the study period that would be expected to influence 
the outcome. These elements are largely not satisfied in studies of COVID-related policy, as 
described below. 
 
ITS relies critically on modelled trends of the outcome over time. Key components of ITS 
analyses include both visual and statistical examination of trends, preferentially alongside a 
theoretical justification of the model used. At a minimum, analyses should provide graphical 
representation of the data and model over time to examine whether pre-trend outcomes are 
stable, all trends are well-fit to the data, “interrupted” at the appropriate time point, and sensibly 
modelled (Figure 2B). In the case where an ITS includes a large number of units (e.g. states), it 
can be difficult to display this information graphically. 
 
One common pitfall in ITS is adoption of inappropriate assumptions on the outcome trend 
(Figure 2C). The estimate of policy impact will be biased if a linear trend is assumed but the 
outcome and response to interventions instead follow nonlinear trends (either before or after the 
policy). In some cases, transformation of the outcome, for example using a log scale, may 
improve the suitability of a linear model, as in Palladino et a., 2020 (27). Imposing linearity 
inappropriately is a serious risk in the context of COVID-19, as trends in infectious disease 
dynamics are inherently non-linear (28). For intuition, terms such as “exponential growth,” 
“flattening,” and “s-curves” all refer to non-linear infectious disease trends. Depending on the 
particular situation, non-linearity or other modelled trends can have complicated and 
counterintuitive impact on policy impact. Apparent linearity may also be temporary and an 
artifact of testing, which may give a misleading impression that linear models for infectious 
disease trends are appropriate indefinitely, as is the case for Zhang et al., 2020 (29).  While 
some use linear progression in order to avoid more complex infectious disease models, in fact, 
linear projections impose strict and often unrealistic models, generally resulting in an 
inappropriate counterfactual. 
 
Researchers can easily misattribute the timing of the policy impact, resulting in spurious 
inference and bias (Figure 2D). Some public health policies can be expected to translate into 
immediate results (e.g., smoking bans and acute coronary events (16)). In contrast, nearly every 
outcome of interest in COVID-19 exhibits complex and difficult to infer time lags (30), typically in 
the realm of many weeks. The time between policy implementation and expected effect in the 
data can be large and highly variable. For example, in order to see the impact of a mask order, 
first the mask order takes effect, then people change their behaviors over time to comply with 
the order (or sometimes the reverse in the case of anticipation effects), mask use behavior 
produces changes in infections, then infections later result in symptoms, symptoms induce 
people to seek testing, the tests must then be processed in labs, and then finally the results get 
reported in data monitoring efforts. Selection of lead/lad time should be justifiable ​a priori​, as 
was done in Islam et al., 2020 (21) and Auger et al., 2020 (31), or external data. Selecting a lag 
based on the data, as in Slavova et al., 2020 (32), risks issues comparable to p-hacking (33). 
 
Finally, and perhaps most concerningly in the context of COVID-19, ITS fails when the policy of 
interest coincides in time with other changes that affect the outcome (Figure 2E) (34). For 
example, if both mask and bar closure orders are rolled out together as a package, ITS cannot 
isolate the impact of bar closures specifically. These changes do not need to have taken place 
exactly concurrently with the policy implementation date of interest; they merely need to have 
some effect within the time period of measurement to result in potentially serious bias in effect 
estimates if unaddressed. ITS will also likely be biased if, during the study period, there is a 
change in the way the outcome data is collected or measured. This might occur if the 
introduction of a COVID-19 control policy is combined with an effort to collect better data on 
infection or mortality cases. Analogously, if an RCT involves randomizing people to a group 
receiving both A and B vs. control, we typically can't disentangle the effects of A from the effects 
of B, unless we also have separate A- and B-only arms. Ultimately, if multiple things are 
changing at the same time, ITS may not be an appropriate design for policy evaluation. 
 
COVID-19 policies rarely arrive alone; they are typically created alongside other policies, 
unofficial action, and large scale behavior changes (35) which themselves impact 
COVID-19-related outcomes. In some cases, anticipation of a policy may induce behavior 
change before the actual policy takes effect. The policies themselves may have been chosen 
due to the expectation of change in disease outcomes, which introduces additional biases 
related to “reverse” causality. 
 
Table 2: Checklist for identifying common pitfalls for ITS to evaluate COVID-19 policy 
Key design questions. 
If any answer is “no,” this analysis is unlikely to be 
appropriate or useful for estimating the impact of the 
intervention of interest. 
Details and suggestions for identifying issues: 
Does the analysis provide graphical representation of the 
outcome over time? 
-Check for a chart that shows the outcome over time, with the dates 
of interest. Outcomes may be aggregated for clarity (e.g. means 
and CIs at discrete time points).  
Is there sufficient pre-intervention data to characterize 
pre-trends in the data? 
-Check the chart(s) to see if there are several time points over a 
reasonable period of time over which to establish stability and 
curvature in the pre-trends. 
Is the pre-trend stable? -Observe if there are sufficient data to reasonably determine a 
stable functional form for the pre-trends, and that they follow a 
modelable functional form. 
Is the functional form of the counterfactual (e.g. linear) 
well-justified and appropriate? 
-Check whether the authors explain and justify their choice of 
functional form. 
-Observe if there is any curvature in the pre-trend. 
-Consider the nature of the outcome. Is it sensible to measure the 
trend of this outcome on the scale and form used? Note: infectious 
disease dynamics are rarely linear. 
-Consider that while pre-trend fit is a necessary condition for an 
appropriate linear counterfactual model, it is not sufficient. Check if 
the authors provide justification for the functional form to continue to 
be of the same functional form (e.g. linear). 
Is the date or time threshold set to the appropriate date or 
time (e.g. is there lag between the intervention and 
outcome)? 
-Check whether the authors justify the use of the date threshold 
relative to the date of the intervention. 
-Trace the process between the intervention being put in place to 
when observable effects in the outcome might appear over time. 
  -Consider whether there are anticipation effects (e.g. do people 
change behaviors before the date when the intervention begins?) 
  -Consider whether there are lag effects. (e.g. does it take time for 
behaviors to change, behavior change to impact infections, 
infections to impact testing, and data to be collected, etc?) 
  -Check if authors appropriately and directly account for these time 
effects. 
Are there concurrent changes that may impact the 
outcome during the measurement period? 
-Consider other policies or interventions which could impact the 
outcome during this time. 
-Consider social behaviors changed which could meaningfully 
impact the outcome during this time. 
-Consider economic conditions changed which could meaningfully 
impact the outcome during this time. 
-Note that the actual concurrent changes do not need to happen 
during the period of measurement, just their effects. 
 
These issues are summarized as a checklist of questions to identify common pitfalls in Table 2. 
Difference-in-differences 
The difference-in-difference (DiD) approach uses concurrent non-intervention groups as a 
counterfactual. Typically, this consists of one set of units (e.g., regions) that had the intervention 
and one set that did not, with each measured before and after the intervention took place. DiD is 
more directly analogous to a non-randomized medical study with at least one treatment and 
control group but limited observation before and after treatment. In contrast to ITS, which 
compares a unit with itself over time, DiD compares differences between treatment arms or units 
at two observation points. In many analyses, a DiD approach is implied by comparing regions 
over time, without formally naming or modelling it. Other DiD approaches use interventions 
implemented at multiple time points (36); see Goodman-Bacon and Marcus (2020) (9) for further 
discussion of the nuances of using those methods to study COVID-19 related policies.  
 
Figure 3: Difference-in-differences 
 
This chart shows one canonical design for DiD (blue, Panel A) and four panels demonstrating 
common issues with DiD analysis (red, panels B-E). In all cases: the blue/red shading 
represents the underlying data trends, the vertical grey line represents the time of 
intervention, the grey dashed lines represent the assumed counterfactual in the absence of 
the intervention. In panel D) the dash-dot line represents the time at which the policy is 
expected to impact the outcome. In panel E), the vertical dotted lines represent concurrent 
events and changes. 
 
One key component of the standard DiD approach is the parallel counterfactual trends 
assumption: that the intervention and comparison groups would have had parallel trends over 
time in the absence of the intervention. In some cases, the parallel trends assumption may be 
referenced or examined implicitly but not named (15). In others, it may not have been stated or 
examined at all (29). 
 
Ideally, pre-intervention trends would be shown to be clearly identifiable, stable, of a similar 
level, and parallel between groups, such as in Hsaing et al 2020 (18). With only one observation 
before and only one after the intervention, assessment of the plausibility of the parallel 
counterfactual trends assumption is not possible. Absent this confirmation (15,37) the evaluation 
runs the risk of biased estimation due to differential pre-trends (Figure 3B). Empirical 
assessment of whether pre-intervention trends were parallel and stable between groups is 
possible when multiple observations are available at multiple time points before the intervention, 
noting that this can begin to resemble a CITS design. In this scenario, pre-trend data should be 
visually and statistically established and documented. While parallel trends before intervention 
(which we can observe and may be testable) do not guarantee parallel ​counterfactual ​trends in 
the post-intervention period (which we cannot observe and are generally untestable), examining 
pre-intervention parallel trends is a minimal requirement for DiD reliability.  
 
It is also important to consider the scale and level on which the outcome is measured (Figure 
3C). As with ITS, if the outcomes in the treatment and comparison groups are moving in parallel 
on a logged scale, they will not be moving in parallel on a natural scale. Level differences by 
themselves may be a problem for COVID-19 outcomes, as infectious disease transmission 
dynamics dictate that infection risks are related to the prevalence of infected people in a 
population, i.e. the rate of change is linked intrinsically to the level. A population with an 
extremely low prevalence will tend to have an inherently slower rise in infection rates than an 
otherwise identical population with merely a low prevalence. Just as importantly, large level 
differences in the outcome between intervention and comparison groups is often indicative of 
other important differences between comparators, which may result in other assumptions being 
violated. 
 
While DiD is in some ways more robust to very specific kinds of timing effects (Figure 3D) and 
concurrent changes (Figure 3E), it also introduces additional risks. DiD effectively doubles the 
opportunity for concurrent changes to spuriously impact results, since they can occur in the 
treatment or comparison groups. As above, this can become even more problematic for DiD in 
the typical case where intervention groups enact more or very contextually different policies 
than non-intervention groups. Even cases where concurrent changes happen equally in both 
treatment and comparison groups can lead to overwhelming bias, particularly when approaching 
the maximum or minimum levels of the outcome. If either the treatment or control group is 
approaching the floor (e.g. 0% prevalence) or ceiling for an outcome of interest due to other 
policies concurrent in both places (e.g. national lockdowns, but region-level differences in mask 
policy), this can lead to bias when comparing changes between the two groups. 
 
Table 3: Checklist for identifying common pitfalls for DiD to evaluate COVID-19 policy 
Key design questions. 
If any answer is “no,” this analysis is unlikely to be 
appropriate or useful for estimating the impact of the 
intervention of interest 
Details and suggestions for inspection: 
Does the analysis provide graphical representation of the 
outcome over time? 
-Check for a graph that shows the outcome over time for all groups, 
with the dates of interest. Outcomes may be aggregated for clarity 
(e.g. mean and CI at discrete time points). 
Is there sufficient pre-intervention data to observe both 
pre and post trends in the data? 
-Check the chart(s) to see if there are several time points over a 
reasonable period of time over which to establish stability and 
curvature in the pre-trends. 
Are the pre-trends stable? -Observe if there are sufficient graphical data to reasonably 
determine a stable functional form for the pre-trends, and that they 
follow a modelable functional form. 
Are the pre-trends parallel? -Observe if the trends in the intervention and comparison groups 
appear to move together at the same rate at the same time. 
Are the pre-trends at a similar level? -Observe if the trends in the intervention and comparison groups 
are at similar levels. 
-Note that non-level trends exacerbates other problems with the 
analysis, including linearity assumptions 
Are intervention and non-groups broadly comparable? -Consider areas where comparison groups may be dissimilar for 
comparison beyond just the level of the outcome. 
Is the date or time threshold set to the appropriate date or 
time (e.g. is there lag between the intervention and 
outcome)? 
-Check whether the authors justify the use of the date threshold 
relative to the date of the intervention. 
-Trace the process between the intervention being put in place to 
when observable effects in the outcome might appear over time. 
  -Consider whether there are anticipation effects (e.g. do people 
change behaviors before the date when the intervention begins?) 
  -Consider whether there are lag effects. (e.g. does it take time for 
behaviors to change, behavior change to impact infections, 
infections to impact testing, and data to be collected, etc?) 
  -Check if authors appropriately and directly account for these time 
effects. 
Are there concurrent changes that may impact the 
outcome during the measurement period? 
-Consider other policies or interventions which could impact the 
outcome during this time. 
-Consider social behaviors changed which could meaningfully 
impact the outcome during this time. 
-Consider economic conditions changed which could meaningfully 
impact the outcome during this time. 
-Note that the actual concurrent changes do not need to happen 
during the period of measurement, just their effects. 
 
Similarly to the ITS section, these issues are summarized as a checklist of questions to identify 
common pitfalls in Table 3. 
Discussion 
In recent months, there has been a proliferation of research evaluating policies related to the 
COVID-19 pandemic. As with other areas of COVID-19 research, quality has been highly 
variable, with low quality studies resulting in poorly or mis-informed policy decisions, wasted 
resources, and undermined trust in research (38,39). To support high quality policy evaluations, 
in this paper we describe common approaches to evaluating policies using observational data, 
and describe key issues that can arise in applying these approaches. We hope that this 
guidance can help support researchers, editors, reviewers, and decision-makers in conducting 
high quality policy evaluations and in assessing the strength of the evidence that has already 
been published. 
 
Policy evaluation — far from a simple task in normal circumstances — is particularly challenging 
during a pandemic. Cross-sectional comparisons of states or countries are likely to be biased by 
selection into treatment: for example, countries with worse outbreaks may be more likely to 
implement policies such as mask requirements. In analyses of changes over time – such as 
single-unit studies using interrupted time-series or multi-unit comparisons using 
difference-in-differences or comparative interrupted time-series – it may not be possible to parse 
apart the effects of different policies implemented around the same time, such as mask 
mandates paired with limits on social gatherings. Analyses of changes over time may also be 
biased if disease or human behavioral dynamics are not modelled appropriately. This can be 
challenging because case counts typically do not grow linearly and there is often a lag between 
a policy change and a behavioral response. 
 
This guidance should be considered minimal screening to identify low quality policy impact 
evaluation in COVID-19, but is in no way sufficient to identify high quality evidence or 
actionability. Beyond the study design and reporting issues described here, policy impact 
evaluation is only as useful as the question it asks, data it uses, and the way it is analyzed. 
Problems with measurement, or changes in measurement overtime (e.g. varying test 
availability), can undermine an otherwise robust evaluation. Research consumers should also 
be wary of instances where the intervention of interest is measured in aggregate but takes place 
on an individual level. This can result in what is known as an “ecological fallacy,” such as a 
situation in which ​areas​ with higher overall mask use have higher transmission, but transmission 
is actually lower for ​individuals ​wearing masks. 
 
In the face of these challenges, we recommend careful scrutiny and attention to potential 
sources of bias in COVID-19-related policy evaluations, but we remain optimistic about the 
potential for robust evaluations to inform decision-making. There are many designs not covered 
by this guidance, including synthetic control (40), adjustment and matching based observational 
causal inference designs (7), instrumental variables and related quasi-experimental approaches 
(41), and randomized controlled trials. Each has its own set of practical, ethical, and inferential 
limitations. Researchers and decision-makers should triangulate across a large variety of 
approaches from theory to evidence, invest in better data and more reliable and useful evidence 
wherever feasible, clearly acknowledge limitations and potential sources of bias, and 
acknowledge when actionable evidence is not feasible (42). We anticipate increasing 
opportunities for better examining policies moving forward, particularly if policies and 
interventions are designed with policy impact evaluation and data collection in mind. 
 
The COVID-19 pandemic requires urgent decisions about policies that affect millions of people’s 
lives in significant ways. High quality evidence on the effects of these policies is critical to 
informing decision-making, but is very hard to generate. Evidence-based decision-making 
depends on research that carefully considers potential sources of bias, and clearly 
communicates underlying assumptions and sources of uncertainty. 
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